Plain-English translation of NCT05556603 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The ASCEND-PANCREATIC study is testing a new blood test that looks for signs of pancreatic cancer by analyzing different markers in your blood — including pieces of cancer DNA, proteins, and other molecules. Researchers hope this blood test could catch pancreatic cancer much earlier than current methods, when it's more treatable. The study will enroll over 7,000 people, including those with pancreatic cancer, benign pancreatic conditions, healthy volunteers, and people at high risk for pancreatic cancer.
Pancreatic cancer is often found too late, when it's harder to treat. Doctors need a simple, early-detection test that can catch this cancer before symptoms appear, similar to blood tests used for other cancers.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will have a single blood draw — a simple needle stick to collect blood for testing. The researchers will analyze your blood sample using special techniques to look for cancer markers. Depending on which group you're in (newly diagnosed with cancer, benign disease, healthy, or high-risk), you may be asked about your medical history, and your results will help researchers develop and validate this new early-detection test.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China
Sponsor
Ruijin Hospital
Collaborators
Guangzhou Burning Rock Dx Co., Ltd.
Enrollment target
~7,062 participants
Started
December 2022
Primary completion
June 2029
Age range
40 Years – 75 Years
Last updated on clinicaltrials.gov in May 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qian Zhan, M.D.
Ruijin Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.